SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)
Non-Hodgkin's Lymphoma
About this trial
This is an interventional treatment trial for Non-Hodgkin's Lymphoma focused on measuring Non-Hodgkin's Lymphoma, NHL, Rituxan, Mantle Cell, mabs
Eligibility Criteria
INCLUSION CRITERIA: Documented B-Cell NHL or mantle cell lymphoma CD-20+ tumor Indolent NHL: follicular B-cell lymphoma, diffuse small lymphoma, marginal zone lymphoma Maximum of three prior chemotherapy regimens Age of at least 18 years at Screening Visit (Site specific requirement may differ) EXCLUSION CRITERIA: Refractory to rituximab, defined as progression of disease while being treated with rituximab or progression within 6 months of the last dose of rituximab (when given either as a single agent or in combination) Previous chemotherapy or immunotherapy within 3 weeks prior to entering the study (6 weeks for nitrosoureas or mitomycin) or failure to recover from adverse events due to any agents administered previously Use of investigational agents within 28 days of study History of prior high dose chemotherapy with allogeneic stem cell support History of prior radioimmunotherapy
Sites / Locations
- Alaska Cancer Research and Education Center
- Bay Area Cancer Research Group
- Wilshire Oncology Medical Group
- USC/Kenneth Norris Jr. Cancer Hospital and Research Institute
- San Diego Cancer Center
- Hematology Oncology, P.C. Carl and Dorothy Bennett Cancer Center
- Georgetown University Medical Center - Lombardi Cancer Center
- Pasco Hernando Oncology
- John B. Amos Cancer Center
- Suburban Hematology & Oncology Associates
- Georgia Oncology Partners Research and Education Foundation
- Northern Indiana Cancer Research Consortium
- Oncology and Hematology
- LSU Health Sciences Center
- Beth Israel/Deaconess Medical Center
- University of Michigan Comprehensive Cancer Center
- Hubert H. Humphrey Cancer Center
- The Cancer Institute of New Jersey
- Arena Oncology Associates
- Long Island Jewish Medical Center
- Upstate NY Cancer Research & Education Foundation, Inc. - Interlakes Oncology/Hematology
- ACORN - West Cancer Center
- Southwest Regional Cancer Center
- Baylor University Medical Center
- Univ. of Virginia Health System-Cancer Center Clinical Trials Office
- Peter MacCallum Cancer Institute
- Royal Melbourne Hospital
- St. Vincent's Hospital
- Westmead Hospital
- Queen Elizabeth II Health Sciences Centre-Victoria General Site
- The Royal Victoria Hospital Cancer Care Program Clinical Trials
- Ottawa Hospital Research Institute
- North Eastern Ontario Regional Cancer Center
- Hopital Notre-Dame Du Chum
Arms of the Study
Arm 1
Experimental
1
open-label, single arm, clinical trial of bendamustine (SDX-105) plus rituximab